Health Condition 1: null- Asthma
Conditions
Interventions
Intervention1: Omalizumab: Dosage-Dose calculation as per serum IgE and Body weight of patient for 12 months (one vial of xolair contains 150mg of omalizumab)
Frequency-once or twice a month for 12 m
Sponsors
Novartis Healthcare Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male or Female, greater than or equal to 12 and less than or equal to 75 years of age 2. Patients with inadequately controlled moderate-to-severe persistent allergic asthma (GINA Stage IV) a. Serum Allergy Test to greater than or equal to 1periennial aeroallergen b. IgE levels greater than or equal to 30 and less than or equal to 1500 IU per mL c. Continuous treatment with high-dose ICS plus LABA greater than or equal to 2 severe exacerbations per year d. Require more than 2 courses of oral corticosteroids in year e. Regular disruptive nocturnal or daytime symptoms as per GINA Stage IV f. FEV1 less than 70%
Exclusion criteria
Exclusion criteria: A patient will be excluded from the study if he or she meets any of the following criteria at baseline: 1. Women who are pregnant, intending to become pregnant *or breastfeeding 2. Patients that have been treated with Xolair® in the past 18 months, 3. Severe medical condition(s) that in the view of the physician prohibits participation in the study e.g. severe renal or hepatic impairment 4. Known hypersensitivity to Xolair® (Omalizumab) or any of the components in the formulation *Intending to become pregnant will be advised medically approved birth control methods like hormonal contraceptives, IUD, and double-barrier contraception. Acceptable methods of contraception may include total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the subject ensures compliance. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception should be maintained throughout the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of Clinically significant asthma exacerbations in patients with severe persistent allergic asthmaTimepoint: at the end of 16, 28 & 52 week of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Reduction in OCS use in patients 2.Number of days missed in work or collage 3.Use of other asthma maintenance medication / rescue medication 4.Worsening of asthma symptoms i.e. Hospitalization, emergency room visits and unscheduled doctor visits 5. Lung function test will be assessed by FEV1, FVC & PEFR 6. Improvement in Asthma Control Score Questionnaires 7. Safety parameters along with serious adverse events 8. Global assessment by physicians & patients will be conductedTimepoint: 1. at baseline and 16, 28 & 52 week. 2. at baseline and 16, 28 & 52 week. 3. at baseline and 16, 28 & 52 week. 4. at 16, 28 & 52 week. 5. at screening , 16, 28 and 52 week. 6. all visits 7. all visits 8. at 16 week , 28 week & 52 week. | — |
Countries
India
Contacts
Public ContactMangala Kotnis
Novartis Healthcare Private Limited
Outcome results
None listed